Destiny Pharma PLC Exercise of Options and Total Voting Rights (7897T)
March 29 2021 - 4:15AM
UK Regulatory
TIDMDEST
RNS Number : 7897T
Destiny Pharma PLC
29 March 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Exercise of Options and Total Voting Rights
Brighton, United Kingdom - 29 March 2021 - Destiny Pharma (AIM:
DEST), a clinical stage innovative biotechnology company focused on
the development of novel medicines that can prevent life
threatening infections, announces that it has issued and allotted
25,000 new ordinary shares of 1 pence each in the capital of the
Company ("Ordinary Shares") following an exercise of share options
by a former employee.
Application will be made to the London Stock Exchange for the
25,000 new Ordinary Shares to be admitted to trading on AIM, with
dealings expected to commence on 2 June 2021 ("Admission").
Following Admission, the Company will have a total of 59,861,921
Ordinary Shares in issue. Shareholders may use this figure of
59,861,921 Ordinary Shares as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which is in a Phase 2b clinical trial targeting the prevention of
post-surgical Staphylococcal hospital infections including MRSA. It
is also co-developing SPOR-COV, a novel, biotherapeutic product for
the prevention of COVID-19 and other viral respiratory infections
and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEUKRKRAVUOURR
(END) Dow Jones Newswires
March 29, 2021 05:15 ET (09:15 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2023 to Apr 2024